Literature DB >> 21099717

Single-copy gain of chromosome 1q is a negative prognostic marker in pediatric nonependymal, nonpilocytic gliomas.

Tomoru Miwa1, Yuichi Hirose, Hikaru Sasaki, Taketo Ezaki, Kazunari Yoshida, Takeshi Kawase.   

Abstract

BACKGROUND: Reports of genetic analyses on pediatric gliomas are few, and those tumors have been far less characterized than adult gliomas.
OBJECTIVE: To characterize the genetic and biological features of pediatric gliomas.
METHODS: We investigated 23 pediatric nonependymal, nonpilocytic gliomas for chromosomal copy number aberrations (CNAs) by comparative genomic hybridization (CGH), mutations of isocitrate dehydrogenase (IDH) genes by direct sequencing, and proliferative activity and expression of O-methylguanine-DNA methyltransferase (MGMT) by immunohistochemistry.
RESULTS: The most frequent CNA was single-copy gain of chromosome 1q, with 10 of 20 successfully investigated tumors showing the abnormality (50%). Other CNAs detected by CGH included gain on 7q (+7q) in 6, +9q in 5, +17q in 5, and + 7p in 4 cases. Gain of entire chromosome 7 was rare (2 cases), and codeletion of 1p and 19q was not detected. Gain of 1q was significantly predictive for shorter progression-free survival (PFS) and overall survival (OS), and even more closely associated with poor clinical outcome than histological grade (P = .0009 for PFS, P = .003 for OS by 1q status; P = .004 for PFS, P = .035 for OS by high-grade vs low-grade). Gain of 1q was also significantly correlated with proliferative activity (P = .0002), and tumors with 1q gain showed a trend toward higher MGMT expression (P = .27). Mutation of IDH1 gene was detected in only 2 of 17 tumors successfully analyzed.
CONCLUSION: Single copy gain of 1q is associated with biological features of pediatric gliomas, and is a negative prognostic marker in patients with those tumors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21099717     DOI: 10.1227/NEU.0b013e3181fd2c2e

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  10 in total

1.  Genetic instability in neural stem cells: an inconvenient truth?

Authors:  Neil J Harrison
Journal:  J Clin Invest       Date:  2012-01-24       Impact factor: 14.808

2.  Upfront chemotherapy and subsequent resection for molecularly defined gliomas.

Authors:  Hikaru Sasaki; Yuichi Hirose; Takahito Yazaki; Yohei Kitamura; Makoto Katayama; Tokuhiro Kimura; Hirokazu Fujiwara; Masahiro Toda; Takayuki Ohira; Kazunari Yoshida
Journal:  J Neurooncol       Date:  2015-05-26       Impact factor: 4.130

3.  Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.

Authors:  Eric J Gratias; Jeffrey S Dome; Lawrence J Jennings; Yueh-Yun Chi; Jing Tian; James Anderson; Paul Grundy; Elizabeth A Mullen; James I Geller; Conrad V Fernandez; Elizabeth J Perlman
Journal:  J Clin Oncol       Date:  2016-07-11       Impact factor: 44.544

4.  Gain of chromosome arm 1q in atypical meningioma correlates with shorter progression-free survival.

Authors:  M Jansen; G Mohapatra; R A Betensky; C Keohane; D N Louis
Journal:  Neuropathol Appl Neurobiol       Date:  2012-04       Impact factor: 8.090

5.  Molecular-genetic and clinicopathological prognostic factors in patients with gliomas showing total 1p19q loss: gain of chromosome 19p and histological grade III negatively correlate with patient's prognosis.

Authors:  Saeko Hayashi; Yohei Kitamura; Yuichi Hirose; Kazunari Yoshida; Hikaru Sasaki
Journal:  J Neurooncol       Date:  2016-12-26       Impact factor: 4.130

Review 6.  Pediatric low-grade gliomas: how modern biology reshapes the clinical field.

Authors:  Guillaume Bergthold; Pratiti Bandopadhayay; Wenya Linda Bi; Lori Ramkissoon; Charles Stiles; Rosalind A Segal; Rameen Beroukhim; Keith L Ligon; Jacques Grill; Mark W Kieran
Journal:  Biochim Biophys Acta       Date:  2014-02-28

7.  Analysis of NADP+-dependent isocitrate dehydrogenase-1/2 gene mutations in pediatric brain tumors: report of a secondary anaplastic astrocytoma carrying the IDH1 mutation.

Authors:  Samantha Mascelli; Alessandro Raso; Roberto Biassoni; Mariasavina Severino; Katrin Sak; Kairit Joost; Claudia Milanaccio; Salvina Barra; Filippo Grillo-Ruggieri; Irene Vanni; Alessandro Consales; Armando Cama; Valeria Capra; Paolo Nozza; Maria Luisa Garrè
Journal:  J Neurooncol       Date:  2012-07-22       Impact factor: 4.506

8.  Molecular-genetic and clinical characteristics of gliomas with astrocytic appearance and total 1p19q loss in a single institutional consecutive cohort.

Authors:  Saeko Hayashi; Hikaru Sasaki; Tokuhiro Kimura; Takayuki Abe; Takumi Nakamura; Yohei Kitamura; Tomoru Miwa; Kaori Kameyama; Yuichi Hirose; Kazunari Yoshida
Journal:  Oncotarget       Date:  2015-06-30

9.  World Health Organization grade II-III astrocytomas consist of genetically distinct tumor lineages.

Authors:  Natsuki Hattori; Yuichi Hirose; Hikaru Sasaki; Shunsuke Nakae; Saeko Hayashi; Shigeo Ohba; Kazuhide Adachi; Takuro Hayashi; Yuya Nishiyama; Mitsuhiro Hasegawa; Masato Abe
Journal:  Cancer Sci       Date:  2016-06-22       Impact factor: 6.716

10.  A pilot study of peptide vaccines for VEGF receptor 1 and 2 in patients with recurrent/progressive high grade glioma.

Authors:  Shunsuke Shibao; Ryo Ueda; Katsuya Saito; Ryogo Kikuchi; Hideaki Nagashima; Atsuhiro Kojima; Hiroshi Kagami; Eriel Sandika Pareira; Hikaru Sasaki; Shinobu Noji; Yutaka Kawakami; Kazunari Yoshida; Masahiro Toda
Journal:  Oncotarget       Date:  2018-04-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.